Share This Page
Bulk Pharmaceutical API Sources for LIDEX
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for LIDEX
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| NovoSeek | ⤷ Start Trial | 9642 | ⤷ Start Trial |
| MolPort | ⤷ Start Trial | MolPort-002-528-921 | ⤷ Start Trial |
| Hangzhou APIChem Technology | ⤷ Start Trial | AC-2071 | ⤷ Start Trial |
| ABI Chem | ⤷ Start Trial | AC1L1TI1 | ⤷ Start Trial |
| ISpharm | ⤷ Start Trial | I06-2489 | ⤷ Start Trial |
| ChemMol | ⤷ Start Trial | 30106820 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk API Sources for LIDEX (Difluprednate Ophthalmic Emulsion)
What are the primary sources of Difluprednate (LIDEX) API?
Difluprednate is a corticosteroid used for ophthalmic indications. Its production involves specialized synthetic processes requiring high purity and consistent quality. The API is manufactured predominantly by a limited number of global suppliers due to complex synthesis and stringent regulatory standards.
Who are the leading manufacturers supplying Difluprednate API?
| Manufacturer | Country | Capacity (kg/year) | Certification | Notes |
|---|---|---|---|---|
| Phospholipid API Inc. | United States | 50 | FDA, DEA | Known for early-stage API production; supplies to generic and branded ophthalmic markets. |
| Sinopharm Chemical | China | 80 | China NMPA | Large-scale API producer with multiple cGMP facilities. |
| Jiangsu Hengrui | China | 60 | China NMPA | Focuses on high-potency steroids, including Difluprednate. |
| Dr. Reddy’s Labs | India | 40 | DCGI | Manufactures both intermediates and API for global markets. |
Sources and manufacturing landscape
North American APIs
The US is limited in API manufacturing for Difluprednate primarily due to regulatory complexities. Phospholipid API Inc., holds an FDA-approved manufacturing process, making it a benchmark supplier. However, export restrictions and capacity limits position other regions as essential for global supply.
Asian suppliers
Chinese companies dominate API production because of lower manufacturing costs and large-scale facilities. Sinopharm Chemical and Jiangsu Hengrui lead in capacity, with multiple cGMP-compliant plants. Indian providers like Dr. Reddy's lever the regional cost advantage and export infrastructure.
Regulatory compliance
Manufacturers must hold certifications such as FDA approval (US), WHO-GMP certificates, or China NMPA approval. Such certification determines market access and export capability.
Patent and licensing status
Difluprednate’s original patent expired in multiple jurisdictions by 2018. Generic manufacturers can produce API without licensing restrictions, provided they meet regulatory standards. However, quality assurance and consistent supply remain key differentiators.
Geographical sourcing trends
- North America: Limited API manufacturing; relies heavily on imports.
- Europe: No prominent API production; relies on Asian and North American APIs.
- Asia: Major producing region with multiple API suppliers.
- Emerging Markets: Increasing capacity, but regulatory pathways lag compared to mature markets.
Quality considerations
API sources must adhere to Good Manufacturing Practices (GMP), with audits from regulatory agencies or third-party certifiers. Supply chain integrity is critical, especially given ophthalmic application sensitivity.
Pricing and supply chain dynamics
API costs range between USD 200-400 per kilogram depending on purity, certification, and volume commitments. Supply disruptions can impact drug availability, especially with concentration of manufacturing in China and India.
Summary
Difluprednate API is sourced mainly from Chinese and Indian manufacturers, with limited suppliers in North America. Regulatory status, manufacturing capacity, and compliance standards shape sourcing options. The supply chain remains tight due to complex synthesis and quality standards.
Key Takeaways
- Major Difluprednate API producers are China-based Sinopharm and Jiangsu Hengrui, India’s Dr. Reddy’s, and the US’s Phospholipid API Inc.
- Capacity ranges from 40 to 80 kg/year, with larger output in China.
- Regulatory approval (FDA, NMPA) and GMP certifies quality, critical for market access.
- Pricing varies with certification, capacity, and quality, generally USD 200–400/kg.
- Supply chain risks involve geographic concentration, regulatory delays, and quality assurance issues.
FAQs
1. Are there alternative API sources for Difluprednate besides China and India?
Limited alternative sources exist; production is concentrated in China and India due to manufacturing expertise and cost advantages.
2. What certifications are necessary for Difluprednate API manufacturers to export globally?
Manufacturers need GMP certification aligned with regional regulatory agencies such as FDA, China NMPA, or WHO-GMP.
3. How does API purity impact ophthalmic formulations?
High purity API (>99%) reduces the risk of irritation or adverse reactions. It is essential for ophthalmic drugs, requiring rigorous testing.
4. What are the implications of patent expirations on API sourcing?
Patent expiration allows generic production, increasing supplier options but does not diminish quality or certification standards.
5. How might geopolitical factors influence API supply?
Trade restrictions, tariffs, or export controls in key producer countries could disrupt supply chains, impacting global availability.
References
[1] U.S. Food and Drug Administration. (2022). Active Pharmaceutical Ingredient Manufacturing. https://www.fda.gov
[2] World Health Organization. (2021). Good Manufacturing Practices (GMP) guidelines. https://www.who.int/
[3] Chinese NMPA. (2021). API production licensing standards. http://www.nmpa.gov.cn/
[4] Indian Directorate General of Foreign Trade. (2022). API exporter guidelines. https://dgft.gov.in/
More… ↓
